Plasma is a strategic resource

Area of Science:

• Biotechnology and Pharmaceutical Sciences
• Public Health and Epidemiology
• Hematology

Background:

• Plasma-derived medicinal products (PDMPs) are essential medicines for treating various conditions, including bleeding disorders and immune deficiencies.
• Global demand for PDMPs is rising, driven by evolving clinical practices and increased patient needs.
• Current plasma collection is heavily concentrated in the US, creating supply chain vulnerabilities.

Purpose of the Study:

• To highlight the critical role of PDMPs and the growing global demand.
• To address the risks associated with the geographic imbalance of plasma collection.
• To advocate for a more equitable and robust global plasma supply chain.

Main Methods:

• Analysis of global plasma collection trends and PDMP manufacturing dependencies.
• Assessment of supply chain risks and potential disruptions.
• Review of policy implications for plasma collection and resource management.

Main Results:

• The US commercial plasma industry dominates global supply, posing risks of shortages due to geographic concentration.
• Increased plasma collection, particularly in low- and middle-income countries, is necessary to meet rising demand.
• Capacity building and policy changes are essential to strengthen global plasma collection efforts.

Conclusions:

• Plasma should be recognized as a strategic resource, comparable to energy and water, due to its critical role in PDMP production.
• Restoring an equitable balance in international plasma supply is crucial to prevent worldwide shortages.
• Global endorsement of strategic plasma independence is recommended to ensure consistent access to essential medicines.